Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q00403
UPID:
TF2B_HUMAN
Alternative names:
General transcription factor TFIIB; S300-II
Alternative UPACC:
Q00403; A8K1A7; Q5JS30
Background:
Transcription initiation factor IIB, also known as General transcription factor TFIIB or S300-II, is pivotal in transcription initiation by RNA polymerase II. It facilitates pre-initiation complex formation and Pol II recruitment at promoter DNA, playing a crucial role in bridging TBP and the Pol II-TFIIF complex. This protein binds to distinct DNA core promoter consensus sequence elements, modulating transcription start site selection.
Therapeutic significance:
Understanding the role of Transcription initiation factor IIB could open doors to potential therapeutic strategies.